Related Experiment Video

Updated: Oct 12, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Pharmacokinetic study of 4-methylumbelliferone in rats: influence of dose on its first-pass hepatic elimination

K Morita, Y Sugiyama, M Hanano

    Journal of Pharmacobio-Dynamics
    |February 1, 1986
    PubMed

    Insights

    First-pass hepatic metabolism of 4-methylumbelliferone (4-MU) is dose-dependent in rats. Increased dosing saturates 4-MU metabolism, significantly impacting its availability and clearance.

    Area of Science:

    • Pharmacology and Toxicology
    • Drug Metabolism and Pharmacokinetics

    Background:

    • First-pass hepatic metabolism significantly influences drug bioavailability.
    • Understanding the pharmacokinetics of 4-methylumbelliferone (4-MU) is crucial for its therapeutic applications.

    Purpose of the Study:

    • To investigate the dose-dependent first-pass hepatic metabolism of 4-MU in rats.
    • To characterize the pharmacokinetics and determine the bioavailability of 4-MU across a range of doses.

    Main Methods:

    • Administered varying doses of 4-MU (17.6 micrograms to 5.29 mg) intravenously and intraportally in rats.
    • Measured plasma concentrations to calculate total body plasma clearance and renal clearance.
    • Assessed the dose-dependency of 4-MU availability.

    Main Results:

    • 4-MU availability increased significantly with dose, ranging from 0.18 to 1.31.
    • Hepatic conjugative metabolism was the primary route of 4-MU clearance.
    • Renal clearance contributed 11-35% to total plasma clearance, varying with dose.

    Conclusions:

    • The marked dose-dependency of 4-MU availability is attributed to saturable hepatic conjugative metabolism.
    • These findings highlight the importance of considering metabolic saturation in 4-MU dosing strategies.

    More Related Videos

    An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

    An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

    Published on: December 3, 2020

    Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug08:28

    Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug

    Published on: December 14, 2021

    Related Concept Videos

    First Pass Effect01:12

    First Pass Effect

    Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
    Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
    Factors Influencing Drug Absorption: Presystemic Elimination01:24

    Factors Influencing Drug Absorption: Presystemic Elimination

    The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
    Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

    Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

    The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
    A study on guinea pigs examined the...
    Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

    Bioavailability Study Design: Single Versus Multiple Dose Studies

    Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
    Measurement of Bioavailability: Pharmacokinetic Methods01:30

    Measurement of Bioavailability: Pharmacokinetic Methods

    Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

    In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...